CLARITY is a randomised controlled trial that aims to establish whether Angiotensin Receptor Blockers (ARBs) reduce the severity of COVID-19.  The trial is being conducted at sites in India and Australia and recruits patients who are admitted to hospital with COVID-19 or, in Australia only, are from a group at risk of severe disease and being monitored at home.  In India, participants will be randomised to receive standard care plus an ARB or standard care plus matched placebo for 28 days.  In Australia, participants will be randomised to standard care plus an ARB or standard care alone. CLARITY will assess the safety and effectiveness of ARBs for COVID-19 treatment